A WhatsApp message has earned Moderna a reprimand from the UK's Prescription Medicines Code of Practice Authority (PMCPA), with Novo Nordisk, Otsuka, AstraZeneca, and Daiichi Sankyo also fo
Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from
Bayer has entered into an alliance with Impli, tapping into the start-up's implantable hormone-monitoring platform, which has potential in fertility treatment and other indications.
A UK initiative to tackle the "historically low" numbers of people taking part in dementia clinical trials has been launched with £20 million ($26 million) in funding from the government.
Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as
Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.